Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125


Is chronic sildenafil therapy safe and clinically beneficial in patients with systolic heart failure?

Amin A, Mahmoudi E, Navid H, Chitsazan M.

Congest Heart Fail. 2013 Mar-Apr;19(2):99-103. doi: 10.1111/chf.12008. Epub 2012 Dec 12.


Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension.

Lewis GD, Shah R, Shahzad K, Camuso JM, Pappagianopoulos PP, Hung J, Tawakol A, Gerszten RE, Systrom DM, Bloch KD, Semigran MJ.

Circulation. 2007 Oct 2;116(14):1555-62. Epub 2007 Sep 4.


Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial.

Simonneau G, Rubin LJ, Galiè N, Barst RJ, Fleming TR, Frost AE, Engel PJ, Kramer MR, Burgess G, Collings L, Cossons N, Sitbon O, Badesch DB; PACES Study Group..

Ann Intern Med. 2008 Oct 21;149(8):521-30. Erratum in: Ann Intern Med. 2009 Jan 6;150(1):63. Ann Intern Med. 2009 Sep 15;151(6):435.


A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension.

Barst RJ, Ivy DD, Gaitan G, Szatmari A, Rudzinski A, Garcia AE, Sastry BK, Pulido T, Layton GR, Serdarevic-Pehar M, Wessel DL.

Circulation. 2012 Jan 17;125(2):324-34. doi: 10.1161/CIRCULATIONAHA.110.016667. Epub 2011 Nov 29.


Effects of 5'-phosphodiesterase four-week long inhibition with sildenafil in patients with chronic heart failure: a double-blind, placebo-controlled clinical trial.

Behling A, Rohde LE, Colombo FC, Goldraich LA, Stein R, Clausell N.

J Card Fail. 2008 Apr;14(3):189-97. doi: 10.1016/j.cardfail.2007.11.006.


Additional use of a phosphodiesterase 5 inhibitor in patients with pulmonary hypertension secondary to chronic systolic heart failure: a meta-analysis.

Wu X, Yang T, Zhou Q, Li S, Huang L.

Eur J Heart Fail. 2014 Apr;16(4):444-53. doi: 10.1002/ejhf.47. Epub 2013 Dec 31.


Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.

Redfield MM, Chen HH, Borlaug BA, Semigran MJ, Lee KL, Lewis G, LeWinter MM, Rouleau JL, Bull DA, Mann DL, Deswal A, Stevenson LW, Givertz MM, Ofili EO, O'Connor CM, Felker GM, Goldsmith SR, Bart BA, McNulty SE, Ibarra JC, Lin G, Oh JK, Patel MR, Kim RJ, Tracy RP, Velazquez EJ, Anstrom KJ, Hernandez AF, Mascette AM, Braunwald E; RELAX Trial..

JAMA. 2013 Mar 27;309(12):1268-77. doi: 10.1001/jama.2013.2024.


Role of oral sildenafil in severe pulmonary arterial hypertension: clinical efficacy and dose response relationship.

Garg N, Sharma MK, Sinha N.

Int J Cardiol. 2007 Sep 3;120(3):306-13. Epub 2006 Dec 15.


Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study.

Guazzi M, Vicenzi M, Arena R, Guazzi MD.

Circulation. 2011 Jul 12;124(2):164-74. doi: 10.1161/CIRCULATIONAHA.110.983866. Epub 2011 Jun 27.


Sildenafil increased exercise capacity during hypoxia at low altitudes and at Mount Everest base camp: a randomized, double-blind, placebo-controlled crossover trial.

Ghofrani HA, Reichenberger F, Kohstall MG, Mrosek EH, Seeger T, Olschewski H, Seeger W, Grimminger F.

Ann Intern Med. 2004 Aug 3;141(3):169-77.


The efficacy and tolerability of sildenafil in patients with moderate-to-severe pulmonary hypertension.

Bharani A, Mathew V, Sahu A, Lunia B.

Indian Heart J. 2003 Jan-Feb;55(1):55-9.


Perioperative sildenafil therapy for pulmonary hypertension in infants undergoing congenital cardiac defect closure.

El Midany AA, Mostafa EA, Azab S, Hassan GA.

Interact Cardiovasc Thorac Surg. 2013 Dec;17(6):963-8. doi: 10.1093/icvts/ivt353. Epub 2013 Aug 28.


Sildenafil citrate therapy for pulmonary arterial hypertension.

Galiè N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Simonneau G; Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group..

N Engl J Med. 2005 Nov 17;353(20):2148-57. Erratum in: N Engl J Med. 2006 Jun 1;354(22):2400-1.


Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension.

Keogh AM, Jabbour A, Weintraub R, Brown K, Hayward CS, Macdonald PS.

J Heart Lung Transplant. 2007 Nov;26(11):1079-83. Epub 2007 Oct 24.


Supplemental Content

Support Center